Atrial Fibrillation Clinical Trial
Official title:
Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)
Verified date | April 2022 |
Source | Ottawa Heart Institute Research Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Atrial fibrillation is the most common heart rhythm disorder. The management of atrial fibrillation is of great importance. Despite the presence of exercise intolerance, weight gain, and an associated decline in overall health and well-being in patients living with atrial fibrillation, recommended standard care does not currently include the prescription of exercise to address these significant health issues. Exercise training is a recognized form of treatment of persons with heart disease. An exercise program such as high-intensity interval training when compared to moderate-intensity continuous exercise training may provide a stronger training stimulus for exercise and clinical outcomes; may be more efficient and motivating; and, may help to improve adherence to exercise training in persistent or permanent atrial fibrillation patients. This has been shown in patients with coronary artery disease and heart failure. The primary objectives of this prospective study are to examine the impact of high-intensity interval training compared to moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.
Status | Active, not recruiting |
Enrollment | 94 |
Est. completion date | October 2030 |
Est. primary completion date | January 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. persistent or permanent atrial fibrillation; 2. rate controlled with a resting ventricular rate of equal to or less than 110 bpm; 3. able to perform a symptom-limited exercise test; 4. at least 40 years of age; 5. patient agrees to sign informed consent. Exclusion Criteria: 1. currently participating in routine exercise training (more than two times per week); 2. unstable angina; 3. uncontrolled diabetes mellitus; 4. diagnosed severe mitral or aortic stenosis; 5. diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction; 6. unable to provide written, informed consent. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Ottawa Heart Insititue | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Heart Institute Research Corporation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in quality of life as measured by the Short-Form 36 questionnaire | Change in quality of life from baseline to 12 weeks as measured by the Short Form-36 questionnaire. | baseline to 12 weeks | |
Primary | Change in exercise capacity as measured by six-minute walk test distance | Change in exercise capacity from baseline to 12 weeks as measured by six-minute walk test distance. | baseline to 12 weeks | |
Secondary | Change in exercise adherence measured by accelerometer | Change in exercise adherence from baseline to 12 weeks as measured by accelerometer. | baseline to 12 weeks | |
Secondary | Change in activity status measured by the Duke Activity Status Index | Change in activity status from baseline to 12 weeks as measured by the Duke Activity Status Index. | baseline to 12 weeks | |
Secondary | Change in symptom burden measured by the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale | Change in symptom burden from baseline to 12 weeks as measured by the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale. | baseline to 12 weeks | |
Secondary | Change in symptom frequency and severity measured using the 7-day symptom diary | Change in symptom frequency and severity from baseline to 12 weeks as measured using the the 7-day symptom diary. | baseline to 12 weeks | |
Secondary | Change in disease specific quality of life will be measured using the University of Toronto Atrial Fibrillation Severity Scale (AFSS) | Change in disease specific quality of life from baseline to 12 weeks will be measured using the University of Toronto Atrial Fibrillation Severity Scale (AFSS). | baseline to 12 weeks | |
Secondary | Change in anxiety and depressive symptoms will be measured using the Hospital Anxiety and Depression Scale (HADS) | Change in anxiety and depressive symptoms from baseline to 12 weeks will be measured using the Hospital Anxiety and Depression Scale (HADS). | baseline to 12 weeks | |
Secondary | Change in sleep apnea risk will be measured by the STOP-BANG Sleep Apnea Questionnaire | Change in risk of sleep apnea from baseline to 12 weeks will be measured by the STOP-BANG Sleep Apnea Questionnaire. | baseline to 12 weeks | |
Secondary | Insomnia severity index will be measured using the Insomnia Severity Index | Insomnia severity index at baseline and 12 weeks will be measured using the Insomnia Severity Index. | baseline to 12 weeks | |
Secondary | Change in self reported sleep patterns will be measured using a 7-day sleep diary | Change in self reported sleep patterns from baseline to 12 weeks will be measured using a 7-day sleep diary. | baseline to 12 weeks | |
Secondary | Change in heart rate control will be measured using 24-hour Holter ECG recordings and ECG recordings at each cardiopulmonary exercise test (CPET) | Change in heart rate control from baseline to 12 weeks will be measured using 24-hour Holter ECG recordings and ECG recordings at each cardiopulmonary exercise test (CPET) | baseline to 12 weeks | |
Secondary | Change in muscular fitness will be measured using standard load tests | Change in muscular fitness from baseline to 12 weeks will be measured using standard load tests. | baseline to 12 weeks | |
Secondary | Change in exercise capacity will be measured using a cardiopulmonary exercise test (CPET) | Change in exercise capacity from baseline to 12 weeks will be measured using a cardiopulmonary exercise test (CPET) | baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |